Volume 2, Article ID 2, Pages 6-14

Along with the antibody based antiangiogenic (AAG) drugs, several small molecular antiangiogenic (sAAG) drugs are also in clinical practice for the treatment of different cancers. Though population based clinical trials have provided their efficacy; however, comparative efficacies of these drugs at molecular level are not available. The drug-target network is highly important to understand the efficacy and toxicity of drugs in terms of systems biology. In this study, multiply molecular docking between sAAG drugs and several target receptors are carried out. Our data suggest that though gefitinib is quite potent in targeting different receptors involved in angigiogenesis, but it may impose some serious side effects within physiological system. Our data also suggest that one sAAG drug have some preferential binding affinity to one receptor while have lower binding capacity for other receptor. Hence different sAAG drugs may produce different types of toxicity within the physiological system. For example, lapatinib has highest binding affinity towards NO synthease, while erlotinib has lowest binding affinity to this enzyme. Similarly, sunitinib has highest binding affinity towards beta-2 receptor, while lapatinib has lowest affinity to this receptor. Hence this work provides the rationality of switching between different sAAG drugs during the course of treatment in the control of toxicity by one sAAG drug without discontinuation of therapy and management of toxicity by other drugs.

Keywords: angiogenesis, toxicity, antiangiogenic drug, small molecular antiangiogenic drug, VEGF, Tyrosine kinase, Her-2.

Download “Demo Download” Demo.pdf – Downloaded 48 times – 4 KB